Thus, treatment of NASH models by using cenicriviroc, an oral dual chemokine receptor CCR2/CCR5 antagonist, reduced infiltration of monocyte-derived macrophages, and ameliorated histological NASH activity and hepatic fibrosis [264]. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.